NCT02963064

JSP191 Antibody Targeting Conditioning in SCID Patients

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of JSP191 for Hematopoietic Cell Transplantation Conditioning to Achieve Engraftment and Immune Reconstitution in Subjects With SCID

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Jasper Therapeutics, Inc. · Industry
• Sex: All
• Age: 3 Months – 12 Years
• Healthy volunteers: Not accepted

Summary

A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency undergoing blood stem cell transplantation

Detailed description

A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with SCID undergoing blood stem cell transplantation. Blood Stem Cell transplantation offers the only potentially curative therapy for SCID. The biological conditioning regimen, JSP191, is an antibody that binds to CD117. CD117 is the receptor for Stem Cell Factor on blood forming cells. CD117 binding to Stem Cell Factor is critical for survival and maintenance of blood forming stem cells. The binding of JSP191 to CD117 blocks CD117 from binding to Stem Cell Factor on blood forming stem cells. In the absence of CD117/Stem Cell Factor binding, hematopoietic stem cells that are currently occupying the bone marrow niches in SCID patients exit from the bone marrow.

Conditions

• SCID

Interventions

Type	Name	Description
BIOLOGICAL	Humanized anti-CD117 Monoclonal Antibody (JSP191)	Procedure: single intravenous infusion of JSP191 antibody

Timeline

• Start date: 2017-03-20
• Primary completion: 2025-07-07
• Completion: 2025-07-07
• First posted: 2016-11-15
• Last updated: 2025-07-28

Locations

9 sites across 1 country: United States

Regulatory

• FDA-regulated drug study